Correspondence 0001178913-25-000114 from Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp
Date: Jan. 14, 2025 · CIK: 0002022416 · Accession: 0001178913-25-000114

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-282932

Date

January 14, 2025

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Silexion Therapeutics Corp

Letter

Re:

January 14, 2025

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Silexion Therapeutics Corp

Registration Statement on Form S-1 (Registration No. 333-282932) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-282932) (the “Registration Statement”), hereby concurs in the request by Silexion Therapeutics Corp that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Wednesday, January 15, 2025, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

    January 14, 2025

    VIA FACSIMILE AND EDGAR

    U.S. Securities and Exchange Commission

    Division of Corporate Finance

    Washington, DC  20549

                Re:

              Silexion Therapeutics Corp

                Registration Statement on Form S-1 (Registration No. 333-282932) -

                Concurrence in Acceleration Request

    Ladies and Gentlemen:

    H.C. Wainwright & Co., LLC (“Wainwright”),
      solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-282932) (the “Registration Statement”),
      hereby concurs in the request by Silexion Therapeutics Corp that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Wednesday, January 15, 2025, or as soon as practicable thereafter, pursuant
      to Rule 461 under the Securities Act.  Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

            Very truly yours,

            H.C. WAINWRIGHT & CO., LLC

            By:
            /s/ Mark W. Vicklund

            Name: Mark W. Vicklund

            Title: Chief Executive Officer

      430 Park Avenue  |  New York, NY 10022  |  212.356.0500  |  www.hcwco.com

      Member: FINRA/SIPC

SecProbe.io